AbCellera Biologics Inc. (NASDAQ:ABCL) Q1 2023 Results Conference Call May 4, 2023 5:00 PM ET
Company Participants
Tryn Stimart - Chief Legal and Compliance Officer
Dr. Carl Hansen - Chairman, Chief Executive Officer, and President
Andrew Booth - Chief Financial Officer
Conference Call Participants
Andrea Tan - Goldman Sachs
Antonia Borovina - Bloom Burton
Stephen Willey - Stifel
Nishant Gandhi - Truist
Gaurav Goparaju - Berenberg
Puneet Souda - SVB Securities
Malcolm Hoffman - BMO
Steven Mah - Cowen
Operator
Good afternoon. And welcome to AbCellera's First Quarter 2023 Business Update Conference Call. My name is Terry, and I will facilitate the audio portion of today's interactive broadcast. [Operator instructions]
At this time, I would like to turn the call over to Tryn Stimart, AbCellera’s Chief Legal and Compliance Officer. Please proceed.
Tryn Stimart
Thank you. Good afternoon, and welcome to AbCellera's first quarter 2023 business update. We're pleased to have you with us today as we will discuss the results announced in our press release issued after the market closed today, which you can find on our investor relations website. With me on the call today are are Dr. Carl Hansen, AbCellera's Chief Executive Officer and President; and Andrew Booth, AbCellera's Chief Financial Officer.
The webcast portion of this call contains a slide presentation that we will refer to during the call. If you are following along on the phone and wish to access the slide portion of this presentation, you may do so on the investor relations section of our website. For those of you who have accessed the streaming portion of the webcast, please be aware that there may be a delay and that you will not be able to post questions via the web.
This presentation may contain forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Act of 1995. Any forward-looking statements are based on management's current expectations and are subject to certain risks and uncertainties. Please review our SEC filings for risk factors that could impact our future performance. Our presentation and SEC filings are available on our investor relations website. Note that all dollars referred to during our call today are U.S. dollars.
Now, I am pleased to turn the call over to Dr. Carl Hansen.
Dr. Carl Hansen
Thank you, Tryn. And thanks everyone for joining us today. It's my pleasure to provide an update on our business for the first quarter of 2023. Through the first quarter, we continue to allocate our resources to the execution of our long-term strategy, investing in building team's technology and infrastructure to create the industry's preferred engine for antibody therapeutics and using this engine with partners to develop a diversified portfolio of stakes in future antibody therapies.